Skip to main content

Table 1 Patient characteristics

From: A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

   N (%)
Sex Male 17 (71)
Female 7 (29)
Age Median 56 years
Range 34 to 75 years
Histology Adenocarcinoma 21 (88)
Others 3 (12)
Stage III 6 (25)
IV 18 (75)
Performance Status 0 15 (63)
1 8 (33)
2 1 (4)
Number of prior lines of chemotherapy 1 1 (4)
  2 or more 23 (96)